Exchange: NASDAQ·Updated 07:04 AM EDT
SINT logo

SINT SINTX Technologies Inc

$1.75
$0.03
(1.74%)
Pre-Market
Prev Close $1.72
Mkt Cap$13M
Vol100.00

About SINT

SINTX Technologies, Inc. is a ceramics company, which engages in the development and commercialization of silicon nitride for medical and non-medical applications. It markets spinal fusion products and develops products for use in total hip and knee joint replacements. The company was founded by Aaron A. Hofmann and Ashok C. Khandkar in December 1996 and is headquartered in Salt Lake City, UT.
69

Bullish Sentiment

How do you feel about SINT?

Boston7452
$SINT 2024 was a massive shareholder oppression move via a 200:1 RS that evidence suggest was planned out well in advance. Then Sintx began the “pivot” away from industrial/defense to kill off any short term revenue & passed a large Emp equity plan that conviently failed to pass before that 200:1 RS in 2023. 2025 represents medical pure play price suppression period when insiders loaded complete with Insider fund Medtech receiving 1/3 of that PIPE offering. Mgmt finished loading before the close of 2025 with Honigblum’s 70+k share purchases. 2026 represents the Varian suppression, hiding of CTO departure, lawsuit, further price erosion to justify giving Bleichroeder(tied to Siemens) & Medtech cheap full price/share ratcheting, hammering of going concern which Sintx mgmt engineered by withholding the Varian news. Now Sintx is pivoting back to advanced ceramics away from pure medical play to justify a preplanned merger with NP.
5
Boston7452
$SINT mgmt purposefully engaging in asset waste in addition to price suppression doesn’t mean no demand. Besides, Varians investment in Ned Medical proves demand which cannot commercialize Combisphere without Sintx. That’s why Varian news should have been disclosed from the market. every reasonable investor would think it’s significant validation of Sintx technology. Hiding that investment is just another example of price suppression.
3
Boston7452
$SINT understand that Sintx mgmt and board have done all this to push through this merger. They would have been planning this since about 2016 when Sintx announced it was working with Morgan Ceramics the former patent company of NP Aerospace. Back then Sintx and Morgan were likely developing the laser cladding technology I’ve talked about. This technology is dual faceted. Applied to ortho implants but can easily be used for the aerospace/defense industries. That’s how we’re were sold this back then, but at some point they decided to monopolize the tech under one umbrella it seems. Sintx has purposefully kept itself tiny for this
3
SnoopyDog
$SINT Share count update: Q1 2024: ~255K shares Q3 2024: 1.34M Q1 2025: ~2.52M Q3 2025: 3.62M Q1 2026: 4.12M Q2 2026: 6.61M Aug 2026: 6.66M After today’s Class B warrant call: ~8.5M shares That’s roughly a 33x increase in outstanding shares in about 2.5 years. Lol Management’s playbook remains the same - burn cash, issue shares, repeat. But its worth billions
2
SnoopyDog
$SINT Care to drop the SEC filing or patent link showing that an $80B titan like Siemens Healthineers / Varian can’t run without SINT?
1
SnoopyDog
$SINT yeah there just were a deal thatvwould have been great. Unfortunately there isnt and its all smoke and mirror/SCAM
1
maxnus159
$SINT It's a turnaround company with major upside ahead: With recent $3.2 million contract manufacturing orders and they began shipping their advanced ceramic compnents already and will continue into 2027. And with fortune 500 aerospace agreements, US missile defense agency contract, and medical & orthopedic contracts. A 380% qtr-over-qtr revenue. The timing is now
1
Geneo12345
$SINT I made thousands here years back, along with some OGs and MIP. That was back in the Sonny days. This thing is an absolute dogg now with zero potential.
1
FastBull
$SINT successfully brought in ~$2 million in cash by forcing warrant holders to convert them or lose them, leaving the company with no remaining Class B warrants and a higher total share count

Advertisement|Remove ads.